MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa2209870

Медицинская библиотека · The New England journal of medicine · 2023

Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.

Jones Jim, Correll Darin J, Lechner Sandra M, Jazic Ina, Miao Xiaopeng, Shaw David, Simard Christopher, Osteen Jeremiah D, Hare Brian, Beaton Alina, Bertoch Todd, Buvanendran Asokumar, Habib Ashraf S, Pizzi Lois J, Pollak Richard A, Weiner Scott G, Bozic Carmen, Negulescu Paul, White Paul F, VX21-548-101 and VX21-548-102 Trial Groups

Рандомизированное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

The NaV1.8 voltage-gated sodium channel, expressed in peripheral nociceptive neurons, plays a role in transmitting nociceptive signals. The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied.

METHODS

After establishing the selectivity of VX-548 for NaV1.8 inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, participants were randomly assigned in a 1:1:1:1 ratio to receive one of the following over a 48-hour period: a 100-mg oral loading dose of VX-548, followed by a 50-mg maintenance dose every 12 hours (the high-dose group); a 60-mg loading dose of VX-548, followed by a 30-mg maintenance dose every 12 hours (the middle-dose group); hydrocodone bitartrate-acetaminophen (5 mg of hydrocodone bitartrate and 325 mg of acetaminophen every 6 hours); or oral placebo every 6 hours. In the bunionectomy trial, participants were randomly assigned in a 2:2:1:2:2 ratio to receive one of the following over a 48-hour treatment period: oral high-dose VX-548; middle-dose VX-548; low-dose VX-548 (a 20-mg loading dose, followed by a 10-mg maintenance dose every 12 hours); oral hydrocodone bitartrate-acetaminophen (5 mg of hydrocodone bitartrate and 325 mg of acetaminophen every 6 hours); or oral placebo every 6 hours. The primary end point was the time-weighted sum of the pain-intensity difference (SPID) over the 48-hour period (SPID48), a measure derived from the score on the Numeric Pain Rating Scale (range, 0 to 10; higher scores indicate greater pain) at 19 time points after the first dose of VX-548 or placebo. The main analysis compared each dose of VX-548 with placebo.

RESULTS

A total of 303 participants were enrolled in the abdominoplasty trial and 274 in the bunionectomy trial. The least-squares mean difference between the high-dose VX-548 and placebo groups in the time-weighted SPID48 was 37.8 (95% confidence interval [CI], 9.2 to 66.4) after abdominoplasty and 36.8 (95% CI, 4.6 to 69.0) after bunionectomy. In both trials, participants who received lower doses of VX-548 had results similar to those with placebo. Headache and constipation were common adverse events with VX-548.

CONCLUSIONS

As compared with placebo, VX-548 at the highest dose, but not at lower doses, reduced acute pain over a period of 48 hours after abdominoplasty or bunionectomy. VX-548 was associated with adverse events that were mild to moderate in severity. (Funded by Vertex Pharmaceuticals; VX21-548-101 and VX21-548-102 ClinicalTrials.gov numbers, NCT04977336 and NCT05034952.).

Для цитирования: Jones Jim, Correll Darin J, Lechner Sandra M, Jazic Ina, Miao Xiaopeng, Shaw David, Simard Christopher, Osteen Jeremiah D, Hare Brian, Beaton Alina, Bertoch Todd, Buvanendran Asokumar, Habib Ashraf S, Pizzi Lois J, Pollak Richard A, Weiner Scott G, Bozic Carmen, Negulescu Paul, White Paul F, VX21-548-101 and VX21-548-102 Trial Groups. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.. The New England journal of medicine. 2023. DOI: 10.1056/nejmoa2209870.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.